Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Qixin Sun, Bingyi Wu, Fanyi Meng, Qianqian Yao, Zhiwei Huang, Jianhui Xu & Zhigang Zhu. (2023) Sorafenib regulates c-CBL gene-mediated chemoresistance in acute myeloid leukemia cells. Hematology 28:1.
Read now
Read now
Articles from other publishers (5)
Franziska Schmidt, Miriam Erlacher, Charlotte Niemeyer, Dirk Reinhardt & Jan-Henning Klusmann. (2022) Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML. Frontiers in Pediatrics 10.
Crossref
Crossref
Suresh Gopi Kalathil, Alan Hutson, Joseph Barbi, Renuka Iyer & Yasmin Thanavala. (2019) Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. JCI Insight 4:15.
Crossref
Crossref
Amir Noeparast, Philippe Giron, Alfiah Noor, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Carolien Eggermont, Hugo Vandenplas, Bram Boeckx, Diether Lambrechts, Jacques De Grève & Erik Teugels. (2019) CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition. Oncogene 38:31, pages 5933-5941.
Crossref
Crossref
Leticia Serrano-Oviedo, Marta Ortega-Muelas, Jesús García-Cano, María Ll. Valero, Francisco J. Cimas, Raquel Pascual-Serra, Diego M. Fernandez-Aroca, Olga Roche, María J. Ruiz-Hidalgo, Borja Belandia, José M. Giménez-Bachs, Antonio S. Salinas & Ricardo Sanchez-Prieto. (2018) Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion. PLOS ONE 13:7, pages e0200878.
Crossref
Crossref
Lifang Luo, Lijing Cai, Laibang Luo, Zhimou Tang & Xiaohui Meng. (2018) Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells. Molecular Medicine Reports.
Crossref
Crossref